Trials / Completed
CompletedNCT00932802
Greatest International Antiinfective Trial With Avelox
GIANT - Greatest International Antiinfective Trial With Avelox®
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50,000 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit (baseline) and at least one short-term follow-up visit (=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were documented, and a patient questionnaire was filled in.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Moxifloxacin (Avelox, BAY12-8039) | AECB patients under daily life treatment receiving moxifloxacin according to the local product information. |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2009-07-03
- Last updated
- 2012-11-19
Locations
24 sites across 24 countries: Austria, Brazil, China, Colombia, Croatia, Egypt, El Salvador, Germany, Hong Kong, Hungary, Indonesia, Malaysia, Mexico, Morocco, Netherlands, Pakistan, Philippines, Poland, Singapore, Slovenia, South Korea, Switzerland, Taiwan, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00932802. Inclusion in this directory is not an endorsement.